Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: hmpa who wrote (7)	4/2/2003 2:46:04 AM
From: nigel bates	Respond to of 4232

The serum of at least 20 patients have been life-saving in the past two weeks for those who were severely ill." A possible play ? (NTP.L : cap c. £30m, bv c.£11m) neutecpharma.com FABTEC© Fabtec® is NeuTec Pharma’s platform technology for the identification of new therapeutic antibody fragments. Fabtec© has recently become available for licensing. Fabtec® consists of four distinct steps Identification and recruitment of appropriate individuals to provide blood specimens Identification of the correct individuals to be included in the study is all important for extracting the best possible data. Information such as age, infection status and general health all influence the success of procedures further down the line. Amplification, cloning and sequencing of antibody fragments Much effort has been put into these steps to ensure that the data we produce matches the range of antibodies expressed in infection. The individual molecular biology techniques used at each stage of the antibody fragment library production have all been optimised in-house. NeuTec’s sequencing facilities allow for the production of up to 500,000 base pairs of data each week, with the option of doubling this capacity. Analysis of sequence data and identification of potential therapeutic antibodies The production of so much data would be pointless without the ability to interpret it. With the lack of any useful software on the market NeuTec bespoke developed software designed to handle the large amounts of antibody fragment data. The Fabtec® Warehouse now represents one of our most important tools in the identification of therapeutic antibodies. Laboratory scale production of antibody fragments and investigation of their properties Expression vectors have been specially designed by our molecular biologists for the expression of antibody fragments. These in-house vectors have been shown to express antibody fragments at high levels. A comprehensive series of tests are performed on the expressed antibody fragments to identify the activity of the antibody fragments and access their suitability for manufacture. NeuTec Pharma have found that this process, for taking a disease from preliminary clinical investigation through to the creation of molecules ready for manufacturing for use in pre-clinical studies, has taken 3-6 months. We believe that NeuTec Pharma is approaching antibody fragment analysis in a unique way. When Fabtec® was initially conceived there existed no academic papers specifically tackling the subject from this angle and no software existed for analysis of the type of data that Fabtec® generates. Several infectious diseases have now been investigated using the Fabtec® methodology and all have thrown out extremely promising molecules. The potential exists for identifying therapeutics to any infectious disease (fungal, bacterial or viral), cancer, rheumatoid arthritis, anti-toxin, in fact any disease in which immunoglobulin have been shown to play an important role.